Down-regulation of the expression of RB18A/MED1, a cofactor of transcription, triggers strong tumorigenic phenotype of human melanoma cells

International Journal of Cancer

Volumn 124, Issue 11, 2009, Pages 2597-2606

  De La Croix Ndong, Jean ^a   Jean, Didier ^a   Rousselet, Nathalie ^a   Frade, Raymond ^a  

^a INSERM   (France)

Author keywords

DRIP205; Melanoma; PBP; RB18A; TIMP 3; TRAP220; Tumor progression; uPAR

Indexed keywords

CATHEPSIN L; GELATINASE A; LAMIN A; LAMIN C; MED1 PROTEIN; RB18A PROTEIN; SMALL INTERFERING RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; MEDIATOR OF RNA POLYMERASE II TRANSCRIPTION SUBUNIT 1;

3' UNTRANSLATED REGION; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CARCINOGENICITY; CELL INVASION; CELL PROLIFERATION; COMPETITIVE INHIBITION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MALE; MELANOMA CELL; MICROARRAY ANALYSIS; MICROENVIRONMENT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; TUMOR CELL LINE; TUMOR GENE; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CANCER INVASION; DRUG ANTAGONISM; GENETICS; MELANOMA; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CELL LINE, TUMOR; DOWN-REGULATION; HUMANS; MALE; MELANOMA; MICE; MICE, INBRED BALB C; NEOPLASM INVASIVENESS; PHENOTYPE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA, SMALL INTERFERING; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TRANSCRIPTION FACTORS;

EID: 64249138743     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24253     Document Type: Article

References (43)

1. Drane P, Barel M, Balbo M, Frade R. Identification of RB18A, a 205 kDa new, p53 regulatory protein which shares antigenic and functional properties with p53. Oncogene 1997;15:3013-3024 (Pubitemid 28043481)
2. Barel M, Fiandino A, Lyamani F, Frade R. Epstein-Barr virus/C3d receptor (EBV/C3dR) reacts with p53, a cellular anti-oncogene-encoded membrane phosphoprotein: detection by polyclonal anti-idiotypic anti-EBV/C3dR antibodies (Ab2). Proc Natl Acad Sci USA 1989;86:10054-10058
3. Yuan CX, Ito M, Fondell JD, Fu ZY, Roeder RG. The TRAP220 component, of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. Proc Natl Acad Sci USA 1998;95:7939-7944 (Correction: 95:14584). (Pubitemid 28326045)
4. Rachez C, Lemon BD, Suldan Z, Bromleigh V, Gamble M, Näär AM, Erdjument-Bromage H, Tempst P, Freedman LP. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 1999;398:824-828 (Pubitemid 129523987)
5. Zhu Y, Qi C, Jain S, Rao MS, Reddy JK. Isolation and characterization of PBP, a protein that interacts with peroxisome proliferator-activated receptor. J Biol Chem 1997;272:25500-25506 (Pubitemid 27438856)
6. Bourbon HM, Aguilera A, Ansari AZ, Asturias FJ, Berk AJ, Bjorklund S, Blackwell TK, Borggrefe T, Carey M, Carlson M, Conaway JW, Conaway RC, et al. An unified nomenclature for protein subunits of mediator complexes linking transcriptional regulators to RNA polymerase II. Mol Cell 2004;14:553-557 (Pubitemid 38739079)
7. Belakavadi M, Fondell JD. Role of the mediator complex in nuclear hormone receptor signaling. Rev Physiol Biochem Pharmacol 2006;156:23-43.
8. Ito M, Yuan CX, Malik S, Gu W, Fondell JD, Yamamura S, Fu ZY, Zhang X, Qin J, Roeder RG. Identity between TRAP and SMCC complexes indicates novel pathways for the function of nuclear receptors and diverse mammalian activators. Mol Cell 1999;3:361-370 (Pubitemid 29290676)
9. Frade R, Balbo M, Barel M. RB18A, whose gene is localized on chromosome 17q12 q21.1, regulates in vivo p53 transactivating. activity. Cancer Res 2000;60:6585-6589
10. Frade R, Balbo M, Barel M. RB18A regulates p53-dependent apoptosis. Oncogene 2002;21:861-866 (Pubitemid 34146299)
11. Lottin-Divoux S, Barel M, Frade R. RB18A enhances expression of mutant p53 protein in human cells. FEBS Lett 2005;579:2323-2326 (Pubitemid 40569499)
12. Crawford SE, Qi C, Misra P, Stellmach V, Rao MS, Engel JD, Zhu Y, Reddy JK. Defects of the heart, eye, and megakaryocytes in peroxisome proliferator activator receptor-binding protein (PBP) null embryos implicate GATA family of transcription factors. J Biol Chem 2002;277:3585-3592 (Pubitemid 34953230)
13. Stumpf M, Waskow C, Krötschel M, van Essen D, Rodriguez P, Zhang X, Guyot B, Roeder RG, Borggrefe T. The mediator complex functions as a coactivator for GATA-1 in erythropoiesis via subunit Med1/TRAP220. Proc Natl Acad Sci USA 2006;103:18504-18509 (Pubitemid 44913440)
14. Matsushita A, Sasaki S, Kashiwabara Y, Nagayama K, Ohba K, Iwaki H, Misawa H, Ishizuka K, Nakamura H. Essential role of GATA2 in the negative regulation of thyrotropin beta gene by thyroid hormone and its receptors. Mol Endocrinol 2007;21:865-884 (Pubitemid 46984728)
15. Wada O, Oishi H, Takada I, Yanagisawa J, Yano T, Kato S. BRCA1 function mediates a TRAP/DRIP complex through direct interaction with TRAP220. Oncogene 2004;23:6000-6005 (Pubitemid 39093545)
16. Udayakumar TS, Belakavadi M, Choi KH, Pandey PK, Fondell JD. Regulation of Aurora-A kinase gene expression via GABP recruitment of TRAP220/MED1. J Biol Chem 2006;281:14691-14699 (Pubitemid 43855174)
17. Zhu Y, Qi C, Jain S, Nye JS, Rao MS, Reddy JK. Deletion of PBP/ PPARBP, the gene for nuclear receptor coactivator peroxisome proliferator- activated receptor-binding protein, results in embryonic lethality. J Biol Chem 2000;275:14779-14782 (Pubitemid 30337186)
18. Ito M, Yuan CX, Okano HJ, Darnell RB, Roeder RG. Involvement of the TRAP220 component of the TRAP/SMCC coactivator complex in embryonic development and thyroid hormone action. Mol Cell 2000;5:683-693
19. Matsumoto K, Yu S, Jia Y, Ahmed MR, Viswakarma N, Sarkar J, Kashireddy PV, Rao MS, Karpus W, Gonzalez FJ, Reddy JK. Critical role for transcription coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein/TRAP220 in liver regeneration and PPARalpha ligand-induced liver tumor development. J Biol Chem 2007;282:17053-17060 (Pubitemid 47093249)
20. Zhu Y, Qi C, Jain S, Le Beau MM, Espinoza R, Atkins GB, Lazar MA, Yeldandi AV, Rao MS, Reddy JK. Amplification and overexpression of peroxisome proliferator-activated receptor binding protein (PBP/PPARBP) gene in breast cancer. Proc Natl Acad Sci USA 1999;96:10848-10853 (Pubitemid 29442232)
21. Vijayvargia R, May MS, Fondell JD. A coregulatory role for the mediator complex in prostate cancer cell proliferation and gene expression. Cancer Res 2007;67:4034-4041 (Pubitemid 46815048)
22. Luca MR, Bar-Eli M. Molecular changes in human melanoma metastasis. Histol Histopathol 1998;13:1225-1231 (Pubitemid 28480377)
23. Frade R, Rodrigues-Lima F, Huang S, Xie K, Guillaume N, Bar-Eli M. Procathepsin L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res 1998;58:2733-2736 (Pubitemid 28311900)
24. Guillaume-Rousselet N, Jean D, Frade R. Cloning and characterization of anti-cathepsin L single chain variable fragment whose expression inhibits procathepsin L secretion in human melanoma cells. Biochem J 2002;367:219-227 (Pubitemid 35176909)
25. Rousselet N,Mills L, Jean D, Tellez C, Bar-EliM, Frade R. Inhibition of tumorigenic and metastatic phenotype of human melanoma cells by anticathepsin L single chain variable fragment. Cancer Res 2004;64:146-151 (Pubitemid 38114092)
26. Frade R, Roussselet N, Jean D. Intratumoral gene delivery of anti-cathepsin L single chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells. Cancer Gene Therapy 2008;15:591-604.
27. de Vries TJ, Quax PH, Denijn M, Verrijp KN, Verheijen JH, Verspaget HW, Weidle UH, Ruiter DJ, van Muijen GN. Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 1994;144:70-81. (Pubitemid 24158361)
28. Duffy MJ, Maguire TM, McDermott EW, O'Higgins N. Urokinase plasminogen activator: a prognostic marker in multiple types of cancer. J Surg Oncol 1999;71:130-135 (Pubitemid 29288493)
29. Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin North Am 2001;60:6585-6589
30. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002;115:3719-3727 (Pubitemid 35203598)
31. Ahonen M, Ala-Aho R, Baker A, George S, Grenman R, Saarialho Kere U, Kahari VM. Antitumour activity and bystander effect of adenovirally delivered tissue inhibitor of metalloproteinases-3. Mol Ther 2002;5:705-715 (Pubitemid 34619063)
32. Apte SS, Olsen BR, Murphy G. The gene structure of tissue inhibitor of metalloproteinases (TIMP)-3 and its inhibitory activities define the distinct TIMP gene family. J Biol Chem 1995;270:14313-14318
33. Yu WH, Yu S, Meng Q, Brew K, Woessner JF. TIMP-3 binds to sulphated glycosaminoglycans of the extracellular matrix. J Biol Chem 2000;275:31226-31232
34. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAMTS5). J Biol Chem 2001;276:12501-12504 (Pubitemid 37385157)
35. Murphy G, Knäuper V, Lee MH, Amour A, Worley JR, Hutton M, Atkinson S, Rapti M, Williamson R. Role of TIMPs (tissue inhibitors of metalloproteinases) in pericellular proteolysis: the specificity is in the detail. Biochem Soc Symp 2003;70:65-80. (Pubitemid 38497216)
36. Dano K, Behrendt N, Brunner N, Ellis V, Ploug M, Pyke C. The urokinase receptor: protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8:189-203. (Pubitemid 24287550)
37. Choong PF, Nadesapillai AP. Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. Clin Orthop Relat Res 2003;415:46-58. (Pubitemid 37323319)
38. Quax PH, van Muijen GN, Weening-Verhoeff EJ, Lund LR, Dano K, Ruiter DJ, Verheijen JH. Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 1991;115:191-199 (Pubitemid 21909905)
39. Ferrier CM, van Muijen GNP, Ruiter DJ. Proteases in cutaneous melanoma. Ann Med 1998;30:431-442 (Pubitemid 28479490)
40. Hofmann UB, Becker JC, Bröcker EB. Role of matrix-degrading enzymes in melanoma progression. Hautarzt 2002;53:587-595 (Pubitemid 36068389)
41. Fidler IJ. The organ microenvironment and cancer metastasis. Differentiation 2002;70:489-505. (Pubitemid 36194315)
42. Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic suppressor elements inhibit melanoma growth and invasion through loss of gap junctional communication. Oncogene 2001;20:4676-4684 (Pubitemid 32762439)
43. Huang S, Mills L, Mian B, Tellez C, McCarty M, Yang XD, Gudas JM, Bar-Eli M. Fully humanized neutralizing antibodies to interleukin- 8 (ABX-IL8) inhibit angiogenesis, tumor growth, and metastasis of human melanoma. Am J Pathol 2002;161:125-134 (Pubitemid 34760778)